Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $107.00.

MNPR has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. Chardan Capital reiterated a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a research report on Monday, February 23rd. Finally, Wall Street Zen upgraded shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $56.25 on Thursday. Monopar Therapeutics has a fifty-two week low of $28.40 and a fifty-two week high of $105.00. The company has a market cap of $376.88 million, a PE ratio of -29.61 and a beta of 1.49. The firm has a fifty day moving average price of $56.97 and a two-hundred day moving average price of $65.54.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. Analysts expect that Monopar Therapeutics will post -4.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently modified their holdings of the business. Ally Bridge Group NY LLC lifted its stake in Monopar Therapeutics by 86.6% in the third quarter. Ally Bridge Group NY LLC now owns 64,455 shares of the company’s stock valued at $5,264,000 after buying an additional 29,918 shares in the last quarter. AlphaQuest LLC lifted its stake in Monopar Therapeutics by 8.5% in the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after buying an additional 151 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at approximately $250,000. Sei Investments Co. raised its holdings in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after purchasing an additional 656 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Monopar Therapeutics by 21.2% in the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock valued at $4,307,000 after purchasing an additional 13,761 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.